Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200577618> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W3200577618 endingPage "iv10" @default.
- W3200577618 startingPage "iv9" @default.
- W3200577618 abstract "Abstract PURPOSE Glioblastomas (GBMs) are highly aggressive brain tumors with poor prognosis. Belinostat is a histone deacetylase inhibitor with blood–brain barrier permeability, anti-GBM activity, and potential to enhance chemoradiation. This clinical trial sought to determine a tolerable dose of concurrent belinostat and assess the clinical efficacy of combining this drug with standard-of-care therapy. METHODS 13 patients each were enrolled in control and belinostat cohorts. The belinostat cohort was given a belinostat regimen (500-750mg/m2 1x/day x 5 days) every 3 weeks (weeks 0, 3, and 6 of RT). All patients received standard temozolomide and radiation therapy (RT). Patient outcomes included progression-free survival, overall survival (OS), and analysis of recurrence pattern of the recurrent gross tumor volume (rGTV). RESULTS Belinostat at 750 mg/m2 produce dose-limiting toxicities (DLTs) in 2 of 3 patients while belinostat at 500 mg/m2 did not result in DLTs. Median OS was 18.5 months for the belinostat cohort and 15.8 months for the control cohort (p=0.53). The rGTVs in the control cohort occurred in areas that received higher radiation doses than that in the belinostat cohort. For those belinostat patients that experienced out-of-field recurrences, tumors were detectable by spectroscopic MRI (sMRI) before RT. In particular, one belinostat patient had an IDH-mutant GBM that had an extraordinary response to therapy with significant shrinkage of enhancing tumor much greater than expected. CONCLUSION Belinostat given concurrently at 500 mg/m2 is well-tolerated. While median OS was not significantly increased for the belinostat cohort, recurrence analysis suggests better in-field control with belinostat, suggesting a radio-sensitizing effect. This study suggests that belinostat can act as a synergistic therapeutic agent for GBMs that may be further enhanced by sMRI-guided RT and may be particularly effective against IDH mutant tumors. A trial is currently in development using belinostat with sMRI-guided RT for IDH-mutant high-grade gliomas." @default.
- W3200577618 created "2021-09-27" @default.
- W3200577618 creator A5002395863 @default.
- W3200577618 creator A5003718738 @default.
- W3200577618 creator A5011008679 @default.
- W3200577618 creator A5012087640 @default.
- W3200577618 creator A5019454697 @default.
- W3200577618 creator A5023012020 @default.
- W3200577618 creator A5033231728 @default.
- W3200577618 creator A5035737725 @default.
- W3200577618 creator A5053850518 @default.
- W3200577618 creator A5061676019 @default.
- W3200577618 creator A5063989253 @default.
- W3200577618 creator A5073162662 @default.
- W3200577618 creator A5082489420 @default.
- W3200577618 creator A5086594299 @default.
- W3200577618 date "2021-09-21" @default.
- W3200577618 modified "2023-09-30" @default.
- W3200577618 title "SYST-07. PILOT STUDY UTILIZING THE HDAC INHIBITOR BELINOSTAT WITH CHEMORADIATION FOR NEWLY-DIAGNOSED GLIOBLASTOMA" @default.
- W3200577618 doi "https://doi.org/10.1093/noajnl/vdab112.035" @default.
- W3200577618 hasPublicationYear "2021" @default.
- W3200577618 type Work @default.
- W3200577618 sameAs 3200577618 @default.
- W3200577618 citedByCount "0" @default.
- W3200577618 crossrefType "journal-article" @default.
- W3200577618 hasAuthorship W3200577618A5002395863 @default.
- W3200577618 hasAuthorship W3200577618A5003718738 @default.
- W3200577618 hasAuthorship W3200577618A5011008679 @default.
- W3200577618 hasAuthorship W3200577618A5012087640 @default.
- W3200577618 hasAuthorship W3200577618A5019454697 @default.
- W3200577618 hasAuthorship W3200577618A5023012020 @default.
- W3200577618 hasAuthorship W3200577618A5033231728 @default.
- W3200577618 hasAuthorship W3200577618A5035737725 @default.
- W3200577618 hasAuthorship W3200577618A5053850518 @default.
- W3200577618 hasAuthorship W3200577618A5061676019 @default.
- W3200577618 hasAuthorship W3200577618A5063989253 @default.
- W3200577618 hasAuthorship W3200577618A5073162662 @default.
- W3200577618 hasAuthorship W3200577618A5082489420 @default.
- W3200577618 hasAuthorship W3200577618A5086594299 @default.
- W3200577618 hasBestOaLocation W32005776181 @default.
- W3200577618 hasConcept C126322002 @default.
- W3200577618 hasConcept C143998085 @default.
- W3200577618 hasConcept C2777389519 @default.
- W3200577618 hasConcept C2781413609 @default.
- W3200577618 hasConcept C509974204 @default.
- W3200577618 hasConcept C535046627 @default.
- W3200577618 hasConcept C71924100 @default.
- W3200577618 hasConcept C72563966 @default.
- W3200577618 hasConceptScore W3200577618C126322002 @default.
- W3200577618 hasConceptScore W3200577618C143998085 @default.
- W3200577618 hasConceptScore W3200577618C2777389519 @default.
- W3200577618 hasConceptScore W3200577618C2781413609 @default.
- W3200577618 hasConceptScore W3200577618C509974204 @default.
- W3200577618 hasConceptScore W3200577618C535046627 @default.
- W3200577618 hasConceptScore W3200577618C71924100 @default.
- W3200577618 hasConceptScore W3200577618C72563966 @default.
- W3200577618 hasIssue "Supplement_4" @default.
- W3200577618 hasLocation W32005776181 @default.
- W3200577618 hasOpenAccess W3200577618 @default.
- W3200577618 hasPrimaryLocation W32005776181 @default.
- W3200577618 hasRelatedWork W182989684 @default.
- W3200577618 hasRelatedWork W2029933304 @default.
- W3200577618 hasRelatedWork W2034544297 @default.
- W3200577618 hasRelatedWork W2104071976 @default.
- W3200577618 hasRelatedWork W2357953144 @default.
- W3200577618 hasRelatedWork W2566967253 @default.
- W3200577618 hasRelatedWork W2805538129 @default.
- W3200577618 hasRelatedWork W2950931626 @default.
- W3200577618 hasRelatedWork W3194058763 @default.
- W3200577618 hasRelatedWork W4295758394 @default.
- W3200577618 hasVolume "3" @default.
- W3200577618 isParatext "false" @default.
- W3200577618 isRetracted "false" @default.
- W3200577618 magId "3200577618" @default.
- W3200577618 workType "article" @default.